REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that Dr. Barry Selick, Threshold's Chief Executive Officer is scheduled to present at the OneMedForumNY Emerging Finance Conference 2011 on Thursday, June 23, at 10:15 a.m. EST in New York City.
A live webcast of the presentation will be available under the Webcast section of the Company’s website.
About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website (www.thresholdpharm.com).
Forward-Looking Statements
Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding TH-302 and its potential therapeutic uses and benefits. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, whether Threshold's Phase 2 trial of TH-302 in patients with advanced pancreatic cancer or any others that Threshold undertakes will confirm the results of earlier trials based on smaller numbers of patients, the time and expense required to conduct such clinical trials and analyze data, Threshold’s ability to develop a commercial formulation of TH-302 and secured adequate supplies, issues arising in the regulatory process and any unanticipated or increased side-effects observed in patients receiving TH-302. Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on May 12, 2011 and is available from the SEC's website (www.sec.gov) and on our website (www.thresholdpharm.com) under the heading "Investors." We do not intend to update any forward-looking statement made in this news release.
CONTACT:
Threshold Pharmaceuticals, Inc.
Denise T. Powell, 650-474-8206
Senior Director, Corporate Communications
[email protected]
KEYWORDS: United States North America California New York
INDUSTRY KEYWORDS: Health Pharmaceutical
MEDIA: